Evidence map›Paper›PMID 42748895›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026

Targeting prostaglandin catabolism via topical nanotherapy rescues vision in ischemic optic neuropathy.

Shweta Modgil, RuSiou Hsu, Mohammad Ali Shariati, Juan A Oses-Prieto, Al Burlingame, Yaping Joyce Liao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shweta ModgilDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA.
RuSiou HsuDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA; Department of Biomedical Engineering, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Mohammad Ali ShariatiDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA.
Juan A Oses-PrietoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Al BurlingameDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Yaping Joyce LiaoDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA; Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: yjliao@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic optic neuropathy is a leading cause of acute vision loss and currently lacks effective therapy. Here, we identify 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the key enzyme responsible for prostaglandin degradation, as a metabolic checkpoint in ischemic optic neurodegeneration. Analysis of human ischemic optic nerve tissue and a murine model of optic nerve ischemia reveals marked upregulation of retinal 15-PGDH, suggesting dysregulated prostaglandin homeostasis after ischemic injury. To therapeutically target this pathway, we develop a nano-micellar formulation of the hydrophobic 15-PGDH inhibitor SW033291 (SW@NM) that enables efficient topical ocular delivery and retinal penetration. Topical administration of SW@NM suppresses retinal 15-PGDH activity, restores PGE

Indexed as

15-PGDHAIONNano-micelleNeuroprotectionOptic neuropathySW033291

Identifiers

PMID42748895
PMCPMC13595216

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.